Key takeaways
- Cord blood plasma is the liquid fraction of umbilical cord blood, rich in signaling factors. Alpha-fetoprotein (AFP) is one such protein with documented immune-regulating activity.
- Reviews describe AFP as an immunomodulator that shifts immune cell populations rather than blunting immunity across the board, which is why it is being explored in autoimmune disease and oncology.
- The interest in young plasma traces to preclinical parabiosis studies in mice, where exposure to young blood improved age-related cognitive measures.
- A Phase 1 randomized, placebo-controlled pilot trial has tested human umbilical cord blood and plasma in pre-frail adults, measuring physical function and a broad panel of aging biomarkers.
- AFP has also been used as a target in a completed Phase 1 cell-therapy trial for liver cancer, illustrating how its biology is being applied in human research.
What are cord blood plasma and AFP?
Cord blood plasma is the liquid portion of blood collected from the umbilical cord and placenta after a healthy birth, once the cellular components are separated out. Because it comes from the very start of life, researchers have long been interested in the mix of proteins, growth factors, and signaling molecules it contains. These are the substances the body uses to grow, repair, and regulate itself.
Alpha-fetoprotein (AFP) is one specific protein found at high levels in the developing fetus and in cord blood. In adults it is normally present only in trace amounts. That contrast is part of why it draws scientific attention: it is a molecule strongly tied to early development that largely disappears later in life. AFP can be studied as part of whole cord blood plasma or considered as an isolated factor in its own right.
How they are thought to work
For AFP, a 2022 review in Trends in Immunology describes the protein as an immunomodulator, meaning it appears to influence and regulate immune cell populations rather than simply stimulating or suppressing immunity across the board. The review details how AFP can limit the activity of natural killer cells, monocytes, and dendritic cells, and can shift dendritic cells toward promoting regulatory T cells. This selective, regulatory behavior is what makes AFP compelling to researchers.
For cord blood plasma more broadly, the thinking borrows from the wider field of young plasma research. The idea is that circulating factors present early in life may carry signals that support tissue and cellular function, and that reintroducing such factors could influence age-related changes. This is a working rationale drawn largely from animal models, and human research is only beginning to test it directly.
Evidence from the lab to early human trials
The foundational data on the young-plasma concept is preclinical. A 2014 study in Nature Medicine using parabiosis, which surgically joins the circulatory systems of young and old mice, reported that exposure to young blood reversed certain age-related cognitive impairments in the older animals, with measurable changes in hippocampal synaptic plasticity. It is a strong rationale, but it is an animal study.
On the human side, the research is early but real. A Phase 1 randomized, double-blind, placebo-controlled pilot trial (NCT02418013, 64 participants) tested fresh cord blood, frozen cord blood, and frozen plasma against placebo in pre-frail adults aged 55 and over. It was designed to assess safety and to track physical performance, grip strength, quality of life, and a broad panel of aging biomarkers including inflammation markers, telomere length, and growth factors such as GDF11. A trial like this tests whether the mouse findings show any signal in people.
On AFP specifically, the published reviews describe its immune-regulating activity, and that biology has been carried into human trials. A completed Phase 1 study (NCT03132792) engineered patients' own T cells to recognize AFP and tested them in advanced hepatocellular carcinoma and other AFP-expressing tumors, with safety and tumor-response data reported. A 2018 review in Therapeutic Delivery frames further potential applications in autoimmune disease and cancer while noting that much of this work is early. The mechanisms are plausible and the early interest is real, but large-scale human outcome data does not yet exist.
What it is being explored for
The areas of exploration follow directly from the biology. Because AFP nudges immune activity toward balance rather than blunt suppression, reviewers discuss it for autoimmune conditions. Because it behaves as a tumor-associated antigen, it has become a target in oncology research. Cord blood plasma, taken as a whole, sits within the broader longevity and healthy-aging conversation, driven by the young-plasma hypothesis and a focus on age-related decline and cellular signaling.
If you are weighing these approaches, the right frame is cautious interest: the biology is genuinely promising, the human evidence is genuinely early, and the two should be held together rather than mistaken for each other.
The evidence
Selected references, each verified against primary sources (PubMed and ClinicalTrials.gov). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Cord Blood Plasma & AFP is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.